House of Lords revisits ‘Biogen’ insufficiency; Novartis’ fluvastatin patent obvious; High Court finds patent for slow release formulation valid but not infringed.
- Published in:
- Journal of Generic Medicines, 2009, v. 6, n. 3, p. 264, doi. 10.1057/jgm.2009.16
- By:
- Publication type:
- Article